

27 November 2014

INVION ANNOUNCES RECEIPT OF R&D TAX CASH REBATE

Invion Limited (ASX:IVX) is pleased to advise that it has received an R&D Tax cash rebate of approximately \$0.79 million, with respect to certain local and overseas R&D activities carried out in the financial year ended 30 June 2014.

Invion currently has an application lodged with AusIndustry which seeks to expand the programs eligible for advance finding under the R&D Tax Incentive Scheme.

Should this application be successful, the Company would be eligible to claim further rebate for local and overseas R&D activities carried out in the financial year ended 30 June 2014. In addition, a greater proportion of R&D expense would be eligible for the rebate in the 2015 and 2016 financial years.

FOR MORE INFORMATION CONTACT:

Managing Director and CEO
Dr Greg Collier
investor@inviongroup.com

MEDIA QUERIES:

Ben Walsh
Buchan Consulting
T: 02 9237 2800 or bwalsh@buchanwe.com.au

About Invion Limited

Invion is a life sciences company focussed on the development of treatments for major opportunities in respiratory disease and autoimmune disease. The Group has three drug assets in development, and three phase II clinical trials, regulated by the Food & Drug Administration (FDA), currently underway in the United States. **INV102 (nadolol)** a beta blocker (beta adrenergic inverse agonist) currently used to treat high blood pressure and migraine, is being repurposed to treat chronic inflammatory airway diseases, including asthma and chronic obstructive pulmonary disease (COPD). **INV104 (zafirlukast)** is a leukotriene receptor antagonist (LTRA) or anti-leukotriene that reduces inflammation, constriction of the airways, and the build-up of mucus in the lungs. **INV103 (ala-Cpn10)** is a modified, naturally occurring human protein which has been proposed as a founding member of the Resolution Associated Molecular Pattern (RAMPs) family hypothesised to maintain and restore immune homeostasis. Invion is an ASX listed company (ASX:IVX), with operations in Brisbane, Australia and Delaware, USA.